The serum pregnancy-specific beta 1-glycoprotein to beta-human chorionic gonadotrophin ratio as an index of prognosis in patients with choriocarcinoma.

Abstract

The ratio of serum pregnancy-specific beta 1-glycoprotein (SP1) to the beta-subunit of human chorionic gonadotrophin (beta-hCG) before and after chemotherapy was measured in 12 patients with metastatic choriocarcinoma. The ratios before chemotherapy ranged between 0.03 and 0.75, with a mean value of 0.34 (SD 0.21). The ratio increased to over 1.0 (1.05-53.3) after one or two courses of chemotherapy in seven of the 12 patients. These women achieved complete remission. In the other five patients who died of the disease due to drug resistance of the tumour, the ratio after chemotherapy was low (0.04-0.74) and tended to decline. These data suggest that the serum SP1/beta-hCG ratio can be used to predict the prognosis of patients with choriocarcinoma.

• Authors: N Sakuragi, H Ohkubo, R Yamamoto, Y Shiina, T Tanaka, K Ichinoe, S Fujimoto
• Journal: British journal of obstetrics and gynaecology (Br J Obstet Gynaecol) Vol. 95 Issue 6 Pg. 614-8 (Jun 1988) ISSN: 0306-5456 [Print] England
• PMID: 2455537 (Publication Type: Journal Article)

Chemical References

• Chorionic Gonadotropin
• Chorionic Gonadotropin, beta Subunit, Human
• Peptide Fragments
• Pregnancy Proteins
• Pregnancy-Specific beta 1-Glycoproteins

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Choriocarcinoma (blood, drug therapy)
• Chorionic Gonadotropin (blood)
• Chorionic Gonadotropin, beta Subunit, Human
• Female
• Humans
• Peptide Fragments (blood)
• Pregnancy
• Pregnancy Proteins (analysis)
• Pregnancy-Specific beta 1-Glycoproteins (analysis)
• Prognosis
• Uterine Neoplasms (blood, drug therapy)